-
公开(公告)号：US12209090B2
公开(公告)日：2025-01-28
申请号：US17430876
申请日：2020-02-14
Applicant: Centre National de la Recherche Scientifique , Université de Strasbourg , ETAT FRANCAIS (Ministère des armées), representé par la Direction Centrale du Service de Santé des Armées
Inventor： Rachid Baati , Richard Brown , José Dias , Alex Maryan-Instone , Jagadeesh Yerri
IPC: C07D473/34 , A61P25/00 , C07D213/42 , C07D213/78 , C07D401/06 , C07D473/02 , C07D519/00
Abstract: The present invention relates to a compound of formula (I), or one of its pharmaceutically acceptable salts: (I) wherein R1, R2 and —X—Y— have specific definitions. It also relates to the use of such a compound in therapy; and to a process for preparing it.
-
2.发明公开公开(公告)号：US20240024513A1
公开(公告)日：2024-01-25
申请号：US17915569
申请日：2021-04-09
Applicant: INSERM - Institut National de la Santé et de la Recherche Médicale , Université de Strasbourg
Inventor： Luc Dupuis , Immaculada Sanjuan Ruiz , Gina Picchiarelli
CPC classification number: A61K48/0066 , C07K14/4702 , C12N15/86 , A61P25/02 , A61P25/28
Abstract: The invention relates to a nucleic acid encoding human FUS protein comprising a sequence having at least 69% sequence identity with the sequence SEQ ID NO 1 of intron 6 and/or a sequence having at least 60% sequence identity with the sequence SEQ ID NO 2 of intron 7, said sequences being located on either side of exon 7, to a recombinant vector comprising said nucleic acid encoding human FUS protein, and their use as medicament in the treatment and/or prevention of amyotrophic lateral sclerosis (ALS). The invention further relates to a pharmaceutical composition comprising said nucleic acid and/or vector for the prevention and/or treatment of amyotrophic lateral sclerosis (ALS). The present invention finds application in the therapeutic, veterinary and diagnostic medical technical fields.
-
公开(公告)号：US20240011094A1
公开(公告)日：2024-01-11
申请号：US18035409
申请日：2021-11-05
Applicant: INSTITUT NATIONAL DE LA SANTÉ ET DE LA RECHERCHE MÉDICALE , CENTRE NATIONAL DE LA RECHERCHE SCIENTIFIQUE (CNRS) , CENTRE HOSPITALIER REGIONAL UNIVERSITAIRE DE LILLE , UNIVERSITÉ DE LILLE , UNIVERSITÉ DE STRASBOURG
Inventor： Paolo GIACOBINI , Vincent PREVOT , Anne-Laurence BOUTILLIER , Nour El Houda MIMOUNI , Isabel PAIVA DE CASTRO
IPC: C12Q1/6883
CPC classification number: C12Q1/6883 , C12Q2600/154 , C12Q2600/158 , C12Q2600/106
Abstract: In the present invention, inventors provide compelling evidence showing that PCOS neuroendocrine reproductive and metabolic dysfunctions are transmitted in PAMH mice for at least three generations. Inventors employed genome-wide methylated DNA immunoprecipitation (MeDIP) analysis to characterize methylated genes in ovaries from control and PAMH mice of the third generation, the first unexposed transgenerational offspring, together with transcriptome analysis in these tissues. Inventors identified many genes with altered transcriptome expression in ovarian tissues of PCOS-animals and they show that several key molecules associated to the PCOS phenotype are epigenetically regulated through DNA hypomethylation. Inventors report that several differentially methylated signatures found in the ovaries of PCOS-like mice are also present in blood samples from women with PCOS and from daughters born to women with PCOS. Accordingly, the present invention relates to methods for diagnosis of the Polycystic Ovary Syndrome (PCOS) through detection of the methylation status of set of gene of the invention in a biological sample obtained from a subject or a patient. The present invention also relates to a method of preventing or treating a Polycystic Ovary Syndrome (PCOS) in a subject in need thereof.
-
4.发明公开公开(公告)号：US20230349922A1
公开(公告)日：2023-11-02
申请号：US18020450
申请日：2021-08-11
Applicant: Université de Strasbourg , INSERM (INSTITUT NATIONAL DE LA SANTÉ ET DE LA RECHERCHE MÉDICALE)
Inventor： Thomas Baumert , Emilie Crouchet
IPC: G01N33/68 , A61K31/506
CPC classification number: G01N33/6893 , A61K31/506 , G01N2500/10
Abstract: The present invention provides Histamine Receptor 2 antagonists and pharmaceutical compositions thereof for use in the treatment or prevention of liver disease, including liver fibrosis and hepato-biliary cancers. The present invention also relates to methods for identifying candidate compounds that are useful in the treatment or prevention of liver disease, including liver fibrosis and hepato-biliary cancers.
-
公开(公告)号：US11718703B2
公开(公告)日：2023-08-08
申请号：US16963347
申请日：2019-01-22
Applicant: TEREOS STARCH & SWEETENERS BELGIUM , CENTRE NATIONAL DE LA RECHERCHE SCIENTIFIQUE , SOPREMA , UNIVERSITÉ DE STRASBOURG
Inventor： Pierre Etienne Bindschendler , Alexandru Sarbu , Rémi Perrin , Pierre Furtwengler , Luc Avérous , Andréas Redl
CPC classification number: C08G18/163 , C08G18/4241 , C08G18/7664 , C08J9/141 , C08G2110/0025 , C08J2203/14 , C08J2205/10
Abstract: A rigid foam or composition allowing a rigid foam to be obtained made from polyurethane and/or polyisocyanurate. The rigid foam or composition includes polyols selected from polyester polyols and polyether polyols; the polyols include: 5 to 50% of a polyester polyol A by weight relative to the total weight of the polyols; and a polyol B selected from polyester polyols B and polyether polyols B. The polyester polyol A is of general formula Rx-Ry-Z-Ry′-Rx′ in which Z is a C3 to C8 alcohol sugar chosen from glycerol, sorbitol, erythritol, xylitol, araditol, ribitol, dulcitol, mannitol and volemitol. Ry and Ry′ are diesters of formula —OOC—Cn-COO— in which n is between 2 and 34, and Rx and Rx′ are identical or different C2 to C12 monoalcohols.
-
Patent Agency Ranking
6.发明申请公开(公告)号：US20230138047A1
公开(公告)日：2023-05-04
申请号：US17755959
申请日：2020-11-12
Applicant: Université de Strasbourg , INSERM (Institut National de la Santé et de la Recherche Médicale) , ALENTIS THERAPEUTICS AG
Inventor： Thomas Baumert , Emilie CROUCHET , Roberto IACONE , Markus MEYER , Natascha ROHLEN , Antonio SAVIANO , Catherine SCHUSTER , Tamas SCHWEIGHOFFER
Abstract: The present invention concerns the use of anti-Claudin-1 monoclonal antibodies, and pharmaceutical compositions thereof, for the prevention and/or treatment of a fibrotic disease in a patient, in particular pulmonary fibrosis, kidney fibrosis or skin fibrosis. Methods of preventing and/or treating pulmonary fibrosis kidney fibrosis or skin fibrosis by administration of such a monoclonal antibody, or a pharmaceutical composition thereof, are also described.
-
公开(公告)号：US20220389019A1
公开(公告)日：2022-12-08
申请号：US17633617
申请日：2020-08-07
Applicant: Université de Strasbourg , Centre National de la Recherche Scientifique , INSERM - Institut National de la Santé et de la Recherche Médicale , Université Grenoble Alpes
Inventor： Didier ROGNAN , Martine SCHMITT , Maxime CAZORLA
IPC: C07D487/04 , A61P25/28
Abstract: The present invention relates to the field of pharmaceutical composition comprising “LIT-TB” derivatives. More particularly it relates to “LIT-TB” derivatives for use in the treatment of neurodegenerative diseases, and more particularly in the treatment of Huntington's disease. The invention also relates to the “LIT-TB” derivatives and preparation thereof.
-
公开(公告)号：US11434882B2
公开(公告)日：2022-09-06
申请号：US16479788
申请日：2018-01-19
Applicant: UNIVERSITÉ DE STRASBOURG , CENTRE NATIONAL DE LA RECHERCHE SCIENTIFIQUE , THE PROVOST, FELLOWS, FOUNDATION SCHOLARD, AND THE OTHER MEMBERS OF BOARD, OF THE COLLEGE OF THE HOLY AND UNDIVIDED TRINITY OF QUEEN ELIZABETH NEAR DUBLIN
Inventor： Thomas Hermans , John Michael David Coey , Peter Dunne , Bernard Doudin
Abstract: Disclosed is a device including at least one circulating zone and at least one fluid including at least one more-paramagnetic liquid and at least one less-paramagnetic liquid forming a liquid-liquid interphase, the device including at least one element generating, in the circulating zone, a magnetic field, wherein the less-paramagnetic liquid is surrounded by the more-paramagnetic liquid in the circulating zone or wherein the more-paramagnetic liquid is surrounded by the less-paramagnetic liquid in the circulating zone. Also disclosed is a method including circulating at least one less-paramagnetic liquid inside one or more circulating zones of a device including at least one circulating zone and at least one more-paramagnetic liquid in the circulating zone.
-
公开(公告)号：US20220096712A1
公开(公告)日：2022-03-31
申请号：US17430119
申请日：2020-02-13
Applicant: INSTITUT NATIONAL DE LA SANTE ET DE LA RECHERCHE MEDICALE (INSERM) , UNIVERSITÉ DE STRASBOURG
Inventor： Fabien BORNERT , Olivier HUCK , Damien OFFNER , Ysia IDOUX-GILLET , François CLAUSS , Nadia BENKIRANE-JESSEL
Abstract: The present invention concerns a biomaterial comprising a scaffold containing a mineral component, wherein said mineral component comprises at least one calcium phosphate compound, and wherein said scaffold has a surface coated with an interrupted coating made of multilayered droplets, said multilayered droplets being droplets composed of at least one layer pair consisting of a layer of polyanions and a layer of polycations.
-
公开(公告)号：US20220081442A1
公开(公告)日：2022-03-17
申请号：US17430876
申请日：2020-02-14
Applicant: Centre National de la Recherche Scientifique , Université de Strasbourg , ETAT FRANCAIS (Ministère des armées), representé par la Direction Centrale du Service de Santé des
Inventor： Rachid BAATI , Richard BROWN , José DIAS , Alex MARYAN-INSTONE , Jagadeesh YERRI
IPC: C07D473/34 , C07D213/42 , C07D401/06 , C07D519/00 , C07D473/02
Abstract: The present invention relates to a compound of formula (I), or one of its pharmaceutically acceptable salts: (I) wherein R1, R2 and —X—Y— have specific definitions. It also relates to the use of such a compound in therapy; and to a process for preparing it.
-
-
-
-
-
-
-
-
-
Search Results
145
records
(took 0.024 seconds)
